Future opportunities in preventing cisplatin induced ototoxicity

Cancer Treatment Reviews

Volumn 32, Issue 5, 2006, Pages 390-397

  van den Berg, J H ^a   Beijnen, J H ^a,b   Balm, A J M ^c   Schellens, J H M ^b,c  

^a NETHERLANDS CANCER INSTITUTE   (Netherlands)

^b UTRECHT UNIVERSITY   (Netherlands)

^c ANTONI VAN LEEUWENHOEK HOSPITAL   (Netherlands)

Author keywords

Chemoprotection; Cisplatin; Otoprotection; Ototoxicity; Transtympanic

Indexed keywords

2 (3 AMINOPROPYLAMINO)ETHANETHIOL; 2 AMINO 4 (METHYLSULFONYL)BUTYRYLGLUTAMYLHISTIDYLPHENYLALANYL DEXTRO LYSYLPHENYLALANINE; 2 CHLORO 6 N CYCLOPENTYLADENOSINE; ACETYLCYSTEINE; ALLOPURINOL; ALPHA TOCOPHEROL; AMIFOSTINE; ANTIOXIDANT; CISPLATIN; CYTOTOXIC AGENT; EBSELEN; ERDOSTEINE; LACTIC ACID; METHIONINE; PHENYLISOPROPYLADENOSINE; REACTIVE OXYGEN METABOLITE; SALICYLIC ACID; SCAVENGER; SEROTONIN 3 ANTAGONIST; SODIUM THIOSULFATE;

ANTINEOPLASTIC ACTIVITY; CLINICAL PRACTICE; CLINICAL TRIAL; COCHLEA FENESTRA; CORTI ORGAN; DISEASE MODEL; DRUG DIFFUSION; DRUG EFFICACY; DRUG INDUCED DISEASE; DRUG MECHANISM; DRUG STRUCTURE; EAR PROTECTION; EARDRUM; EXTERNAL AUDITORY CANAL; HAIR CELL; HUMAN; INNER EAR; MALIGNANT NEOPLASTIC DISEASE; NAUSEA; NAUSEA AND VOMITING; NEPHROTOXICITY; NEUROPATHY; NEUROTOXICITY; NONHUMAN; OTOTOXICITY; QUALITY OF LIFE; REVIEW; SOLID TUMOR;

ADRENOCORTICOTROPIC HORMONE; AMIFOSTINE; ANIMALS; ANTINEOPLASTIC AGENTS; CISPLATIN; HEARING LOSS; HUMANS; PEPTIDE FRAGMENTS; PROTECTIVE AGENTS;

EID: 33746007179     PISSN: 03057372     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ctrv.2006.04.011     Document Type: Review

References (52)

1. Pinzani V., Bressolle F., Haug I.J., et al. Cisplatin-induced renal toxicity and toxicity-modulating strategies: a review. Cancer Chemother Pharmacol 35 (1994) 1-9
2. Bokemeyer C., Berger C.C., Hartmann J.T., et al. Analysis of risk factors for cisplatin-induced ototoxicity in patients with testicular cancer. Br J Cancer 77 (1998) 1355-1362
3. de Jongh F.E., van Veen R.N., Veltman S.J., et al. Weekly high-dose cisplatin is a feasible treatment option: analysis on prognostic factors for toxicity in 400 patients. Br J Cancer 88 (2003) 1199-1206
4. Rademaker-Lakhai J.M., Crul M., Zuur L., et al. Relationship between cisplatin administration and the development of ototoxicity. J Clin Oncol 24 (2006) 918-924
5. Cardinaal R.M., De Groot J.C., Huizing E.H., Veldman J.E., and Smoorenburg G.F. Cisplatin-induced ototoxicity: morphological evidence of spontaneous outer hair cell recovery in albino guinea pigs?. Hear Res 144 (2000) 147-156
6. van Ruijven M.W., De Groot J.C., and Smoorenburg G.F. Time sequence of degeneration pattern in the guinea pig cochlea during cisplatin administration. A quantitative histological study. Hear Res 197 (2004) 44-54
7. Hinojosa R., Riggs L.C., Strauss M., and Matz G.J. Temporal bone histopathology of cisplatin ototoxicity. Am J Otol 16 (1995) 731-740
8. Smoorenburg G.F., De Groot J.C., Hamers F.P., and Klis S.F. Protection and spontaneous recovery from cisplatin-induced hearing loss. Ann N Y Acad Sci 884 (1999) 192-210
9. van Ruijven M.W., De Groot J.C., Klis S.F., and Smoorenburg G.F. The cochlear targets of cisplatin: an electrophysiological and morphological time-sequence study. Hear Res 205 (2005) 241-248
10. Kopke R.D., Liu W., Gabaizadeh R., et al. Use of organotypic cultures of Corti's organ to study the protective effects of antioxidant molecules on cisplatin-induced damage of auditory hair cells. Am J Otol 18 (1997) 559-571
11. Rybak L.P., Ravi R., and Somani S.M. Mechanism of protection by diethyldithiocarbamate against cisplatin ototoxicity: antioxidant system. Fundam Appl Toxicol 26 (1995) 293-300
12. Feghali J.G., Liu W., and Van de Water T.R. l-n-Acetyl-cysteine protection against cisplatin-induced auditory neuronal and hair cell toxicity. Laryngoscope 111 (2001) 1147-1155
13. Kelly T.C., Whitworth C.A., Husain K., and Rybak L.P. Aminoguanidine reduces cisplatin ototoxicity. Hear Res 186 (2003) 10-16
14. Watanabe K., Hess A., Michel O., and Yagi T. Nitric oxide synthase inhibitor reduces the apoptotic change in the cisplatin-treated cochlea of guinea pigs. Anticancer Drugs 11 (2000) 731-735
15. Iraz M., Kalcioglu M.T., Kizilay A., and Karatas E. Aminoguanidine prevents ototoxicity induced by cisplatin in rats. Ann Clin Lab Sci 35 (2005) 329-335
16. 2+, and the hydrolysis product of cisplatin in the rat. Cancer Chemother Pharmacol 29 (1991) 29-32
17. Ekborn A., Lindberg A., Laurell G., et al. Ototoxicity, nephrotoxicity and pharmacokinetics of cisplatin and its monohydrated complex in the guinea pig. Cancer Chemother Pharmacol 51 (2003) 36-42
18. Rybak L.P., and Kelly T. Ototoxicity: bioprotective mechanisms. Curr Opin Otolaryngol Head Neck Surg 11 (2003) 328-333
19. Hospers G.A., Eisenhauer E.A., and de Vries E.G. The sulfhydryl containing compounds WR-2721 and glutathione as radio- and chemoprotective agents. A review, indications for use and prospects. Br J Cancer 80 (1999) 629-638
20. Treskes M., Nijtmans L.G., Fichtinger-Schepman A.M., and van der Vijgh W.J. Effects of the modulating agent WR2721 and its main metabolites on the formation and stability of cisplatin-DNA adducts in vitro in comparison to the effects of thiosulphate and diethyldithiocarbamate. Biochem Pharmacol 43 (1992) 1013-1019
21. Ekborn A., Hansson J., Ehrsson H., et al. High-dose cisplatin with amifostine: ototoxicity and pharmacokinetics. Laryngoscope 114 (2004) 1660-1667
22. Planting A.S., Catimel G., de Mulder P.H., et al. Randomized study of a short course of weekly cisplatin with or without amifostine in advanced head and neck cancer. EORTC Head and Neck Cooperative Group. Ann Oncol 10 (1999) 693-700
23. Neuwelt E.A., Pagel M.A., Hasler B.P., Deloughery T.G., and Muldoon L.L. Therapeutic efficacy of aortic administration of N-acetylcysteine as a chemoprotectant against bone marrow toxicity after intracarotid administration of alkylators, with or without glutathione depletion in a rat model. Cancer Res 61 (2001) 7868-7874
24. Dickey D.T., Muldoon L.L., Kraemer D.F., and Neuwelt E.A. Protection against cisplatin-induced ototoxicity by N-acetylcysteine in a rat model. Hear Res 193 (2004) 25-30
25. Choe W.T., Chinosornvatana N., and Chang K.W. Prevention of cisplatin ototoxicity using transtympanic N-acetylcysteine and lactate. Otol Neurotol 25 (2004) 910-915
26. Wu Y.J., Muldoon L.L., and Neuwelt E.A. The chemoprotective agent N-acetylcysteine blocks cisplatin-induced apoptosis through caspase signaling pathway. J Pharmacol Exp Ther 312 (2005) 424-431
27. Wang J., Lloyd Faulconbridge R.V., Fetoni A., et al. Local application of sodium thiosulfate prevents cisplatin-induced hearing loss in the guinea pig. Neuropharmacology 45 (2003) 380-393
28. Wimmer C., Mees K., Stumpf P., et al. Round window application of d-methionine, sodium thiosulfate, brain-derived neurotrophic factor, and fibroblast growth factor-2 in cisplatin-induced ototoxicity. Otol Neurotol 25 (2004) 33-40
29. Li G., Sha S.H., Zotova E., et al. Salicylate protects hearing and kidney function from cisplatin toxicity without compromising its oncolytic action. Lab Invest 82 (2002) 585-596
30. Minami S.B., Sha S.H., and Schacht J. Antioxidant protection in a new animal model of cisplatin-induced ototoxicity. Hear Res 198 (2004) 137-143
31. Kalkanis J.G., Whitworth C., and Rybak L.P. Vitamin E reduces cisplatin ototoxicity. Laryngoscope 114 (2004) 538-542
32. Campbell K.C., Meech R.P., Rybak L.P., and Hughes L.F. The effect of d-methionine on cochlear oxidative state with and without cisplatin administration: mechanisms of otoprotection. J Am Acad Audiol 14 (2003) 144-156
33. Ekborn A., Laurell G., Johnstrom P., et al. d-Methionine and cisplatin ototoxicity in the guinea pig: d-methionine influences cisplatin pharmacokinetics. Hear Res 165 (2002) 53-61
34. Deegan P.M., Pratt I.S., and Ryan M.P. The nephrotoxicity, cytotoxicity and renal handling of a cisplatin-methionine complex in male Wistar rats. Toxicology 89 (1994) 1-14
35. Korver K.D., Rybak L.P., Whitworth C., and Campbell K.M. Round window application of d-methionine provides complete cisplatin otoprotection. Otolaryngol Head Neck Surg 126 (2002) 683-689
36. Li G., Frenz D.A., Brahmblatt S., et al. Round window membrane delivery of l-methionine provides protection from cisplatin ototoxicity without compromising chemotherapeutic efficacy. Neurotoxicology 22 (2001) 163-176
37. Rybak L.P., Husain K., Morris C., Whitworth C., and Somani S. Effect of protective agents against cisplatin ototoxicity. Am J Otol 21 (2000) 513-520
38. Lynch E.D., Gu R., Pierce C., and Kil J. Reduction of acute cisplatin ototoxicity and nephrotoxicity in rats by oral administration of allopurinol and ebselen. Hear Res 201 (2005) 81-89
39. Lynch E.D., Gu R., Pierce C., and Kil J. Combined oral delivery of ebselen and allopurinol reduces multiple cisplatin toxicities in rat breast and ovarian cancer models while enhancing anti-tumor activity. Anticancer Drugs 16 (2005) 569-579
40. Kalcioglu M.T., Kizilay A., Gulec M., et al. The protective effect of erdosteine against ototoxicity induced by cisplatin in rats. Eur Arch Otorhinolaryngol (2005)
41. Ford M.S., Nie Z., Whitworth C., Rybak L.P., and Ramkumar V. Up-regulation of adenosine receptors in the cochlea by cisplatin. Hear Res 111 (1997) 143-152
42. Ford M.S., Maggirwar S.B., Rybak L.P., Whitworth C., and Ramkumar V. Expression and function of adenosine receptors in the chinchilla cochlea. Hear Res 105 (1997) 130-140
43. Whitworth C.A., Ramkumar V., Jones B., Tsukasaki N., and Rybak L.P. Protection against cisplatin ototoxicity by adenosine agonists. Biochem Pharmacol 67 (2004) 1801-1807
44. van der Hoop R.G., Vecht C.J., van der Burg M.E., et al. Prevention of cisplatin neurotoxicity with an ACTH(4-9) analogue in patients with ovarian cancer. N Engl J Med 322 (1990) 89-94
45. Hamers F.P., Wijbenga J., Wolters F.L., et al. Cisplatin ototoxicity involves organ of Corti, stria vascularis and spiral ganglion: modulation by alphaMSH and ORG 2766. Audiol Neurootol 8 (2003) 305-315
46. Dickey D.T., Wu Y.J., Muldoon L.L., and Neuwelt E.A. Protection against cisplatin-induced toxicities by N-acetylcysteine and sodium thiosulfate as assessed at the molecular, cellular, and in vivo levels. J Pharmacol Exp Ther 314 (2005) 1052-1058
47. Light J.P., and Silverstein H. Transtympanic perfusion: indications and limitations. Curr Opin Otolaryngol Head Neck Surg 12 (2004) 378-383
48. Hoffmann K.K., and Silverstein H. Inner ear perfusion: indications and applications. Curr Opin Otolaryngol Head Neck Surg 11 (2003) 334-339
49. Goycoolea M.V., and Lundman L. Round window membrane. Structure function and permeability: a review. Microsc Res Tech 36 (1997) 201-211
50. Lundman L., Bagger-Sjoback D., Holmquist L., and Juhn S. Round window membrane permeability. An in vitro model. Acta Otolaryngol Suppl 457 (1989) 73-77
51. Lundman L.A., Holmquist L., and Bagger-Sjoback D. Round window membrane permeability. An in vitro model. Acta Otolaryngol 104 (1987) 472-480
52. Laurell G., Teixeira M., Sterkers O., et al. Local administration of antioxidants to the inner ear. Kinetics and distribution(1). Hear Res 173 (2002) 198-209